There are many myths around premarket approval, such as the idea that PMAs always require clinical data or that it isn’t possible to point to a predicate or substantial equivalence in the filing, Drues said during his latest podcast with Medical Design & Outsourcing.
FDA itself has been offering more guidance around the PMA process and proposing ways to make PMAs less scary for medtech innovators.
You may also like:
Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.
DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Early Registration is now open.